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Abstract: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. At diagnosis,
the majority of patients have villous atrophy in the small bowel mucosa. The objective of this
study was to investigate whether the presence or absence of villous atrophy at diagnosis affects the
long-term prognosis of DH. Data were gathered from the patient records of 352 DH and 248 coeliac
disease patients, and follow-up data via questionnaires from 181 DH and 128 coeliac disease patients
on a gluten-free diet (GFD). Of the DH patients, 72% had villous atrophy when DH was diagnosed,
and these patients were significantly younger at diagnosis compared to those with normal small
bowel mucosa (37 vs. 54 years, p < 0.001). Clinical recovery on a GFD did not differ significantly
between the DH groups, nor did current adherence to a GFD, the presence of long-term illnesses,
coeliac disease-related complications or gastrointestinal symptoms, or quality of life. By contrast,
the coeliac disease controls had more often osteopenia/osteoporosis, thyroid diseases, malignancies
and current gastrointestinal symptoms compared to the DH patients. In conclusion, villous atrophy
at the time of DH diagnosis does not have an impact on the clinical recovery or long-term general
health of DH patients.
Keywords: dermatitis herpetiformis; coeliac disease; gluten-free diet; small bowel; villous
atrophy; prognosis
1. Introduction
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease currently
affecting approximately 13% of coeliac disease patients [1,2]. DH induces intense pruritus and a
symmetrical papulovesicular rash typically on the elbows, knees, and buttocks [3]. Coeliac disease and
DH are genetically predisposed by the human leukocyte antigen (HLA) DQ2 or DQ8 haplotypes, and
exogenous gluten causes an immune response and small bowel mucosal injury in both [4,5]. Furthermore,
autoantibodies against endogenous enzyme tissue transglutaminase (TG2) are characteristically present
in the serum and the intestine in both conditions [6–9].
Diagnosis of DH is verified with the detection of pathognomonic granular immunoglobulin A
(IgA) deposits in the uninvolved skin by direct immunofluorescence (IF) examination [10]. This IgA is
known to target epidermal transglutaminase (TG3) [11], which is considered the autoantigen in DH,
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while in coeliac disease it is TG2 [6]. In addition to the skin, TG3 antibody response is often present in
the sera of DH patients, although TG3 antibodies are occasionally also found in the serum of some
coeliac disease patients without DH [12–14].
At the time of the DH diagnosis, some degree of small bowel mucosal villous atrophy is known to
exist in approximately 75% of patients, but the remainder have normal villous architecture with only
coeliac-type inflammation [15,16]. Regardless of the small bowel mucosal alterations, DH patients only
rarely present with obvious gastrointestinal symptoms [17,18].
A strict life-long gluten-free diet (GFD) is the mainstay of treatment in both DH and coeliac
disease. However, resolution of DH rash can take months or even longer on the dietary treatment, and
therefore, DH patients with severe skin symptoms are additionally treated with dapsone medication
to control the rash more quickly [3,19]. Coeliac disease and DH both carry an increased risk of
concomitant autoimmune conditions such as thyroid diseases and type 1-diabetes; furthermore,
the risk of developing non-Hodgkin lymphoma is increased [20–22]. Mortality in coeliac disease,
but not in DH, has shown to be increased [23]. A GFD is known to have a preventive effect against
the development of lymphoma in DH [24], but other than that, previous research about the factors
influencing the prognosis of DH is lacking. Currently, it is not known whether DH patients with small
bowel villous atrophy at diagnosis have a worse outcome compared to those with normal small bowel
mucosa, and furthermore, whether the prognosis of DH patients with villous atrophy is corresponding
to that of classical coeliac disease patients. This issue is of importance when necessary investigations,
at the time of DH diagnosis, are assessed.
The aim of the current study was to assess whether the presence of villous atrophy at DH diagnosis
would affect clinical recovery on a GFD or the long-term prognosis of DH. In addition, DH patients
were compared to classical coeliac disease controls with abdominal symptoms at diagnosis and a
histologically confirmed diagnosis. The hypothesis of this study was that the presence or absence of
villous atrophy at diagnosis would not be an influential factor in the prognosis of DH.
2. Materials and Methods
Between 1970 and 2014, a total of 526 DH patients were diagnosed at the Department of
Dermatology, Tampere University Hospital. During the study period, all patients with DH living
in a defined area around Tampere were diagnosed at this dermatology unit since IF biopsies required
for the diagnosis were not performed elsewhere. Each DH patient’s diagnosis was based on the typical
clinical picture and the demonstration of granular IgA deposits in skin biopsies [10]. In addition,
all diagnosed patients were routinely suggested to undergo gastroscopy and small bowel biopsy
obtainment at the time of the diagnosis while on a gluten-containing diet. After diagnosis, a strict
GFD was advised to all patients and dapsone was instituted in those with severe skin symptoms.
According to routine treatment policies, all patients were followed up at a DH outpatient clinic
until the rash had cleared and the dapsone medication could be discontinued. In this study, all DH
patients without prior coeliac disease diagnosis (made ≥2 years earlier) diagnosed between 1970 and
2014 and having an available small bowel biopsy result and commencing on a GFD after diagnosis,
were included as study patients. Altogether, 352 DH patients fulfilled the inclusion criteria and
were included as DH study patients. Further, 248 classical coeliac disease patients with abdominal
symptoms at diagnosis and a histologically confirmed diagnosis at Tampere University Hospital
during the same time period served as controls.
Data on demographic characteristics, the severity of clinical symptoms and small bowel mucosal
histology, and the results of coeliac autoantibodies and hemoglobin values at the time of DH or coeliac
disease diagnosis were gathered from the patient records of Tampere University Hospital between
March and October 2016. The small bowel biopsy results were graded as subtotal villous atrophy (SVA),
partial villous atrophy (PVA), or normal mucosa according to the analysis of the routine pathologist
as previously described [16]. In DH patients, the skin symptoms at the time of the diagnosis were
graded as mild, moderate, or severe according to the presence of a few, several or many blisters,
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macular eruptions and erosions. The grading was performed by one dermatologist. In addition,
the commencement and duration of dapsone medication after diagnosis was recorded.
Follow-up data were collected using questionnaires (see below for more detail) mailed to all
294 living DH patients fulfilling the inclusion criteria of this study (on December 2015) and the 222 living
coeliac disease controls (on May 2016). The final response rate was 62% for the DH patients and 58% for
the coeliac disease patients; hence, the follow-up study included 181 DH and 128 coeliac disease patients.
The study protocol and usage of the register-based data were approved by the Regional Ethics
Committee of Tampere University Hospital (R15143), and furthermore, informed consent was obtained
from each patient participating in the follow-up study.
2.1. Questionnaires
The disease-specific questionnaire designed for this study, the Psychological General Well-Being
(PGWB) [25] and Gastrointestinal Symptom Rating Scale (GSRS) [26] questionnaires were mailed to the
DH and coeliac disease study patients. PGWB and GSRS questionnaires are validated questionnaires,
which have been widely applied in previous coeliac disease studies [27–31]. In addition, the DH
patients received the Dermatology Life Quality Index (DLQI) questionnaire [32].
The disease-specific questionnaire included both open and multiple-choice questions. The patients
were asked about the presence and duration of DH and coeliac disease-related symptoms before and
after the diagnosis, the strictness of the GFD, smoking and other lifestyle characteristics, the number of
children born, the family history of coeliac disease or DH, and the patient’s current height and weight.
Compliance with a GFD was reported as strict diet without dietary lapses, dietary lapses once per
month, dietary lapses one to five times per month, or dietary lapses once per week. In addition, the
questionnaire included questions about the presence of coeliac disease complications and associated
diseases, malignancies, other long-term illnesses, and the regular usage of physician-prescribed
medications and over-the-counter (OTC) medications. In the malignancy analysis, non-melanoma skin
cancers were excluded, as were excessive trauma fractures in bone fracture analyses.
As previously described, the validated 22-item PGWB questionnaire evaluates self-perceived
health-related well-being and distress and includes six dimensions: Anxiety, depressed mood, positive
well-being, self-control, vitality, and general health [25]. The total score ranges from 22 to 132,
with a higher score indicating better quality of life. The 15-item GSRS questionnaire assesses
the severity and existence of gastrointestinal symptoms in five categories: Diarrhea, indigestion,
constipation, abdominal pain, and reflux [26]. It uses a seven-point Likert scale for each question:
One indicates an absence of symptoms and seven indicates severe symptoms. The DLQI is a 10-item
dermatology-specific quality of life instrument. The questionnaire includes six different sections:
Symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment
unit. The scores of all ten questions are calculated together, and the total score varies from a minimum
of 0 to a maximum of 30, with a higher score indicating a more impaired life quality [32].
2.2. Statistical Analysis
A Two-sided chi-squared test was used to compare the categorical variables and a Kruskall–Wallis
test was performed to assess differences between the continuous variables. Logistic regression analysis
was used to standardize the study groups according to age at the time of the study. Statistical significance
was set at p < 0.05. The analyses were performed using IBM SPSS Statistics for Windows (Version 23.0.,
IBM Corp., Armonk, NY, USA).
3. Results
3.1. DH Patients with Normal Villous Architecture Compared to DH Patients with Villous Atrophy at Diagnosis
Of the 352 DH patients, 98 (28%) had normal villous architecture, and 254 (72%) had small bowel
mucosal villous atrophy (PVA or SVA) at the time of the DH diagnosis (Table 1). GFD was not initiated
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before the diagnosis in study participants. Mean time since the year of DH diagnosis, was 20 years in
the DH patients with normal villous architecture and 23 years in the DH patients with villous atrophy,
and the difference was not statistically significant. The median age at diagnosis was significantly
higher in the DH patients with normal villous architecture compared to the DH patients with villous
atrophy (p < 0.001, Table 1). At diagnosis, the DH patients with villous atrophy were significantly
more often serum coeliac autoantibody-positive compared to the DH patients with normal villous
architecture (73% vs. 39%, p < 0.001, Table 1). The severity of the DH rash at diagnosis did not differ
significantly between the DH groups (p = 0.862). Eighty percent of all DH patients used dapsone after
the diagnosis. The duration of dapsone usage was longer in the DH patients with normal villous
architecture compared to the DH patients with villous atrophy at diagnosis (median 36 vs. 24 months),
but the difference was not statistically significant (p = 0.097, Table 1).
Table 1. Demographic data and disease-related characteristics of 98 dermatitis herpetiformis (DH)
patients with normal small bowel villous architecture and 254 DH patients with villous atrophy at
diagnosis, and 248 coeliac disease (CD) control patients.







Females; n (%) 50 (51) 125 (49) 193 (78) <0.001
Age at diagnosis; median (range) 52 (3–84) 37 (4–78) 42 (7–75) <0.001 a
Coeliac autoantibodies 1 present in the serum at diagnosis; n (%) 28/72 (39) 139/191 (73) 124/148 (84) <0.001 a
Haemoglobin level at diagnosis 2, g/L; median (Q1–Q3) 3 138 (128–148) 136 (129–146) 130 (121–140) 0.057
Dapsone treatment used; n (%) 75/93 (81) 191/243 (79) - -
Duration of dapsone treatment, months; median (range) 36 (5–324) 24 (2–384) - -
* p-value measured across the three study groups; 1 Transglutaminase 2-, endomysium-, or antireticulin IgA
antibodies; 2 Statistical analysis was further performed for patients ≥16 years of age and for females and males
separately—there were no statistically significant differences between the three groups; 3 Interquartile range;
a Statistically significant difference (p < 0.001) between DH patients with normal villous architecture and DH
patients with villous atrophy.
Of the 181 DH patients with available follow-up data, 39 (22%) had normal villous architecture,
and 142 (78%) had villous atrophy at the time of DH diagnosis. The median follow-up time was
20 years in patients with normal villous architecture and 23 years in the DH patients with villous
atrophy at diagnosis (Table 2). The presence of gastrointestinal symptoms at diagnosis did not differ
between the DH study groups according to the follow-up study questionnaire (p = 0.170). At the time
of the follow-up study, DH patients with normal villous architecture were significantly older compared
to those DH patients who had villous atrophy at diagnosis (Table 2).
The strictness of the GFD and BMI did not differ between the DH study groups at the time of
the study (Table 2). Similarly, no significant differences were detected in smoking habits or physical
activity: 3% of DH patients without villous atrophy and 13% of patients with villous atrophy at
diagnosis were current smokers, and 49% and 69% exercised at least three times a week, respectively.
Table 2. Follow-up data of 39 dermatitis herpetiformis (DH) patients with normal villous architecture
and 142 DH patients with small bowel mucosal villous atrophy at diagnosis, and 128 coeliac disease
(CD) control patients.







Females; n (%) 18 (46) 67 (47) 104 (81) <0.001
Follow-up time, years; median (range) 20 (1–44) 23 (1–42) 18 (6–43) 0.003
Age; median (range) 68 (52–85) 61 (18–96) 65 (34–85) <0.001 a
BMI, kg/m2; median (range) 25 (19–37) 25 (16–38) 26 (15–46) 0.772
Strict adherence to GFD, no dietary lapses; n (%) 30 (77) 101 (71) 107 (84) 0.170 b
Number of long-term illnesses; median (range) 1 (0–7) 1 (0–14) 2 (0–9) <0.001
Number of prescription medications used; median (range) 2 (0–11) 1 (0–18) 3 (0–16) 0.078
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Table 2. Cont.







Uses statin medication; n (%) 14 (36) 21 (15) 15 (12) 0.001 c
Uses antihypertensive medication; n (%) 20 (51) 50 (35) 49 (38) 0.188
Uses proton pump inhibitor medication; n (%) 5 (13) 16 (11) 16 (13) 0.938
Number of over-the-counter medications used; median (range) 0 (0–5) 1 (0–7) 2 (0–7) <0.001
Number of children born; median (range) 2 (0–5) 2 (0–6) 2 (0–5) 0.497
First-degree relatives with DH or CD; n (%) 13 (33) 53 (37) 55 (43) 0.464
BMI: Body mass index; GFD: Gluten-free diet. * p-value measured across the three study groups; a Statistically
significant difference (p < 0.001) between DH patients with normal villous architecture and DH patients with villous
atrophy at diagnosis; b p-value was tested for categorical variables including categories: strict diet, dietary lapses
once per month, dietary lapses 1–5 times/month, dietary lapses once per week; c Statistically significant difference
(p = 0.003) between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
At the time of the follow-up study, coronary heart disease and hypertension were significantly
more common among the DH patients with normal villous architecture compared to the DH patients
with villous atrophy at diagnosis (Figure 1); however, after adjustment for the current age, significant
differences disappeared (p = 0.198, OR = 0.482 and p = 0.273, OR = 0.653, respectively). Significant
differences were not detected in the presence of type 1- or 2-diabetes, thyroid diseases, cerebrovascular
diseases, osteopenia or osteoporosis, or malignancies between the DH study groups (Figure 1). Patients
with self-reported bone fractures were slightly more numerous among the DH patients with villous
atrophy than among those with normal villous architecture at diagnosis, but the difference was not
statistically significant (p = 0.321, Figure 1).
Figure 1. Percentages of dermatitis herpetiformis (DH) patients with normal small bowel mucosal
villous architecture and with villous atrophy at diagnosis, and coeliac disease control patients with
long-term illnesses or complications at the time of the follow-up study. (a) Statistically significant
difference (p < 0.05) between the three study groups; (b) statistically significant difference (p < 0.05)
between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
Statistically significant differences were not detected in the use of physician-prescribed regular
medications between the DH study groups; even the significant difference in the use of statin
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medication disappeared after adjustment for the current age (OR = 0.479, p = 0.88, Table 2). Furthermore,
the total amount of used OTC medications was similar in the DH groups; only the usage of vitamin D
was more frequent among DH patients with villous atrophy at diagnosis compared to those without
villous atrophy (40% vs. 23%, p = 0.050).
The presence of gastrointestinal symptoms or the quality of life according to the total or the
subscores of the GSRS, PGWB (Table 3) and DLQI questionnaires at the time of the study did not differ
between the DH study groups
Table 3. The Psychological General Well-Being (PGWB) and Gastrointestinal Symptom Rating Scale
(GSRS) questionnaires’ median and interquartile range (Q1–Q3) results for the gluten-free diet-treated
dermatitis herpetiformis (DH) patients with normal villous architecture and with villous atrophy at






Architecture (n = 39)
With Villous Atrophy
(n = 142)
PGWB median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 110 (99–116) 110 (101–117) 106 (96–117) 0.200
Anxiety 26 (23–27) 26 (23–27) 25 (23–28) 0.891
Depression 17 (16–18) 17 (16–18) 17 (15–18) 0.587
Well-being 18 (16–20) 18 (16–20) 18 (16–20) 0.279
Self-control 16 (15–17) 16 (15–17) 16 (14–17) 0.295
General health 13 (12–15) 14 (12–16) 13 (11–15) 0.022
Vitality 20 (17–21) 19 (17–21) 18 (16–20) 0.104
GSRS median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 1.6 (1.3–2.0) 1.7 (1.3–2.3) 2.1 (1.5–4.2) <0.001
Diarrhoea 1.0 (1.0–1.7) 1.3 (1.0–2.3) 1.7 (1.0–2.7) 0.006
Indigestion 1.8 (1.5–2.5) 2.0 (1.5–2.5) 2.0 (1.5–3.0) 0.227
Constipation 1.7 (1.0–2.3) 1.7 (1.0–2.3) 1.7 (1.0–2.4) 0.482
Pain 1.3 (1.0–1.7) 1.7 (1.0–2.0) 1.7 (1.3–2.3) 0.007
Reflux 1.0 (1.0–1.5) 1.0 (1.0–2.0) 1.5 (1.0–2.0) 0.084
* p-value measured across the three study groups.
3.2. Comparisons between the DH Patients and the Classical Coeliac Disease Controls
Compared to the DH patients, the coeliac disease controls were more often female (Tables 1 and 2),
and their median diagnostic age was significantly lower compared to DH patients with normal villous
architecture at diagnosis (Table 1).
In the long-term follow-up data, there were no observed differences in current smoking habits
or physical activity between the DH patients and the coeliac disease controls. By contrast, the total
number of long-term illnesses was found to be higher among the coeliac disease controls compared
to the DH patients (Table 2). More specifically, after adjustment for the current age, thyroid diseases
(OR = 3.443, p = 0.019) and osteopenia or osteoporosis (OR = 14.132, p = 0.012) were more common
among the coeliac disease controls than among the DH patients (Figure 1). However, the presence of
self-reported bone fractures did not differ significantly between the DH study groups and the coeliac
disease controls. In the malignancy analysis, the coeliac disease controls outnumbered the DH patients
after adjustment for the current age (OR = 6.527, p = 0.016) (Figure 1).
In the analysis of regularly used physician-prescribed medications and after adjustment for the
current age, the coeliac disease controls were found to use less statin medication compared to the DH
patients with normal villous architecture (OR = 0.319, p = 0.01). In turn, the total number of regularly
used OTCs was higher among the coeliac disease patients compared to the DH patients (p = 0.003,
Table 2), and specifically the use of calcium (p = 0.011) and vitamin D (p < 0.001) was more common.
Quality of life measured with the PGWB did not differ between the coeliac disease controls and
the DH patients with normal villous architecture at diagnosis, but the coeliac disease controls had
significantly lower PGWB general health scores compared to the DH patients with villous atrophy at
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diagnosis (Table 3). In the GSRS questionnaire, the coeliac disease controls had significantly higher
total symptoms gastrointestinal pain and diarrhea scores compared to both DH groups.
4. Discussion
This study demonstrated that the disease severity and the clinical response to a GFD does not
differ between DH patients with normal villous architecture and those with villous atrophy at diagnosis.
Furthermore, the long-term general health and well-being of DH patients are not influenced by the
severity of small bowel mucosal damage at the time of DH diagnosis. The outcomes of the current
study were obtained from a large, prospectively collected series of DH patients, all of whom adhered
to a GFD treatment. Furthermore, in the present study, the proportions of DH patients with villous
atrophy and normal villous architecture were consistent with the findings in earlier DH studies [15,33].
In our previous study, the presence of villous atrophy at DH diagnosis was found to be associated
with a delayed diagnosis, i.e., the presence of the rash for two years or more before the diagnosis,
suggesting that prolonged diagnosis might enable the small bowel mucosal damage to progress [34].
In the current study, the occurrence of villous atrophy did not associate with the severity of the rash
or with the presence of gastrointestinal symptoms at diagnosis. The duration of dapsone medication
was considered the most reliable method of determining the active period of rash after adherence to
a GFD since the majority of patients used dapsone medication, and the medicine was discontinued
as early as possible without a relapse in skin symptoms. The median duration of dapsone usage in
DH study groups corresponded well with previous GFD treatment studies [35,36], and even though
the duration was longer in DH patients with normal small bowel mucosa than in those with villous
atrophy at diagnosis, the difference was not statistically significant. Therefore, presence or absence of
small bowel villous atrophy at diagnosis seems not to influence the clinical recovery of the DH rash.
The long-term follow-up performed in the present DH patients further demonstrated that small
bowel villous atrophy at diagnosis did not have any impact on the presence of long-term illnesses
and complications, or long-term quality of life or the presence of persistent gastrointestinal symptoms.
Additionally, our previous study showed that the mortality of DH patients with villous atrophy
at diagnosis does not differ from that of DH patients with normal villous architecture, and in fact,
the mortality of DH patients was shown to be lower than in the general population [37]. Therefore,
all these results show that DH patients with and without villous atrophy at diagnosis have a similar
good long-term prognosis when they adhere to a GFD.
In contrast to DH, the mortality rate of the patients with coeliac disease are known to be increased
compared to the general population [23,38]. Moreover, when the GFD-treated coeliac disease patients in
the current study were compared to the DH patient groups, they had significantly more malignancies
and long-term illnesses, especially thyroid diseases and osteopenia or osteoporosis. A previous
comparison between DH and coeliac disease also showed a higher frequency of diseases of autoimmune
origin in patients with coeliac disease [39], but then another study demonstrated that autoimmune
diseases were as common among DH patients without classical coeliac disease symptoms than in
those DH patients with preceding coeliac disease diagnosis [40]. In the present study, the coeliac
disease controls were further found to have worse self-reported general health, and they had more
gastrointestinal symptoms at the time of the study compared to the DH patients. These results fit
with our recent study that likewise found a better quality of life and fewer gastrointestinal symptoms
among long-term treated DH patients compared to treated coeliac disease patients [41].
The results of the present study thus suggest that the prognosis of different phenotypes of coeliac
disease diverge and villous atrophy is not the determinative factor in the outcome of DH. Different
adherence rates to GFD or varying lifestyle habits did not explain the outcome differences between
coeliac disease and DH study patients in this study. One explanation for the different prognosis
between coeliac disease and DH might be slightly diverse autoimmune reactions, but this remains to
be elucidated in future studies.
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In the current study, the median age at diagnosis in DH patients with normal villous architecture
was significantly higher compared to DH patients with villous atrophy. We were aware from our earlier
long-term DH studies that the age at diagnosis had increased significantly from 1970 onwards [1], and
further, that there was a significant trend towards milder villous atrophy [16]. However, in the present
study, the time period of DH diagnosis did not differ significantly between DH study groups. Therefore,
the divergence in diagnostic periods does not explain the difference in the diagnostic age between DH
patients with and without villous atrophy at diagnosis. One explanation might be, however, that older
patients are more prone to develop milder small bowel mucosal alterations, e.g., due to divergent
immune responses. Previous research shows that older coeliac disease patients are more likely to
remain seronegative and further, a trend toward less severe histopathology has been observed with
increasing age at the time of coeliac disease diagnosis [42,43]. Nonetheless, these age-related findings
detected in coeliac disease and DH should be examined in more detail in further studies.
As a possible limitation of the current study, it must be recognized that the follow-up data were
obtained from questionnaires, which might cause selection bias. Recall bias is always a possibility when
requiring data from several decades ago. The disease-specific questionnaire used in the study was
designed for this particular study and for comparing the results of the study groups, and it has not been
used in other disease studies, and it has not been validated. GSRS is not optimized for coeliac disease,
but it has been the most commonly used generic questionnaire in coeliac disease studies [28]. PGWB is
not a disease-specific instrument, and therefore, it is possible that it might not assess all of the issues
that are having an impact on life in DH and coeliac disease patients. GSRS and PGWB questionnaires
have not been validated specifically for coeliac disease. Furthermore, all study patients were recruited
from the same hospital, and in the future, results from a more comprehensive geographical distribution
would be of value. In turn, the major strengths of the study are: A well-defined, prospectively collected
DH cohort from a high prevalence area with excellent dietary adherence rates, and the long follow-up
time [1]. Moreover, similar large DH studies with knowledge about the diagnostic small bowel mucosal
findings and long-term follow-up data consisting of GFD adherence rates have not been performed
previously to our knowledge.
5. Conclusions
The major outcome of this study is that skin IgA-IF proven DH patients evincing coeliac-type
small bowel mucosal villous atrophy at diagnosis does not differ from DH patients with non-atrophic
small bowel mucosa with regard to GFD treatment response, long-term quality of life, or the presence
of chronic illnesses or coeliac disease-associated complications.
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